Peringatan Keamanan

Data regarding overdoses of daratumumab are not readily available.L13290,L13296 Patients should be treated with symptomatic and supportive measures.L13290,L13296

Daratumumab

DB09331

biotech approved

Deskripsi

Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab.A7935 It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind.A199002

Daratumumab was granted FDA approval on 16 November 2015.L13290 It is approved for the treatment of multiple myeloma as monotherapy or combination therapy and light chain (AL) amyloidosis in combination with other drugs.L13290,L13296

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Intravenous daratumumab has a terminal half life of 18 ± 9 days.[L13290] Subcutaneous daratumumab has a half life of 20 days.[L13296]
Volume Distribusi Daratumumab intravenous monotherapy has a volume of distribution of 4.7 ± 1.3L and the combination therapy has a volume of distribution of 4.4 ± 1.5L.[L13290] Subcutaneous daratumumab has a volume of distribution of the central compartment of 5.2L and a volume of distribution of the peripheral compartment of 3.8L.[L13296]
Klirens (Clearance) Intravenous daratumumab has a clearance of 171.4 ± 95.3mL/day.[L13290] Subcutaneous daratumumab has a clearance of 119mL/day.[L13296]

Absorpsi

Subcutaneous daratumumab reaches a Cmax of 592µg/mL compared to intravenous daratumumab, which reaches a Cmax of 688µg/mL.L13296 The AUC of subcutaneous daratumumab is 4017µg/mL\*day compared to intravenous daratumumab, which has an AUC of 4019µg/mL\*day.L13296

Metabolisme

Monoclonal antibodies are expected to be metabolized to smaller proteins and amino acids by proteolytic enzymes.A19126

Rute Eliminasi

Monoclonal antibodies are metabolized to amino acids used for synthesis of new proteins or are eliminated by the kidneys.A19126

Interaksi Obat

411 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Daratumumab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Daratumumab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Daratumumab.
Estrone Estrone may increase the thrombogenic activities of Daratumumab.
Estradiol Estradiol may increase the thrombogenic activities of Daratumumab.
Dienestrol Dienestrol may increase the thrombogenic activities of Daratumumab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Daratumumab.
Mestranol Mestranol may increase the thrombogenic activities of Daratumumab.
Estriol Estriol may increase the thrombogenic activities of Daratumumab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Daratumumab.
Quinestrol Quinestrol may increase the thrombogenic activities of Daratumumab.
Hexestrol Hexestrol may increase the thrombogenic activities of Daratumumab.
Tibolone Tibolone may increase the thrombogenic activities of Daratumumab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Daratumumab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Daratumumab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Daratumumab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Daratumumab.
Zeranol Zeranol may increase the thrombogenic activities of Daratumumab.
Equol Equol may increase the thrombogenic activities of Daratumumab.
Promestriene Promestriene may increase the thrombogenic activities of Daratumumab.
Methallenestril Methallenestril may increase the thrombogenic activities of Daratumumab.
Epimestrol Epimestrol may increase the thrombogenic activities of Daratumumab.
Moxestrol Moxestrol may increase the thrombogenic activities of Daratumumab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Daratumumab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Daratumumab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Daratumumab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Daratumumab.
Biochanin A Biochanin A may increase the thrombogenic activities of Daratumumab.
Formononetin Formononetin may increase the thrombogenic activities of Daratumumab.
Estetrol Estetrol may increase the thrombogenic activities of Daratumumab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Daratumumab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Daratumumab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Daratumumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Daratumumab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Daratumumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Daratumumab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Daratumumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Daratumumab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Daratumumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Daratumumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Daratumumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Daratumumab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Daratumumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Daratumumab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Daratumumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Daratumumab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Daratumumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Daratumumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Daratumumab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Daratumumab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Daratumumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Daratumumab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Daratumumab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Daratumumab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Daratumumab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Daratumumab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Daratumumab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Daratumumab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Daratumumab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Daratumumab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Daratumumab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Daratumumab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Daratumumab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Daratumumab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Daratumumab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Daratumumab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Daratumumab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Daratumumab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Daratumumab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Daratumumab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Daratumumab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Daratumumab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Daratumumab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Daratumumab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Daratumumab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Daratumumab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Daratumumab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Daratumumab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Daratumumab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Daratumumab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Daratumumab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Daratumumab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Daratumumab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Daratumumab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Daratumumab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Daratumumab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Daratumumab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Daratumumab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Daratumumab.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Daratumumab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Daratumumab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Daratumumab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Daratumumab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Daratumumab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Daratumumab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Daratumumab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Daratumumab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Daratumumab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Daratumumab.
Lumiliximab The risk or severity of adverse effects can be increased when Lumiliximab is combined with Daratumumab.

Target Protein

ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 CD38

Referensi & Sumber

Artikel (PubMed)
  • PMID: 26729183
    McKeage K: Daratumumab: First Global Approval. Drugs. 2016 Feb;76(2):275-81. doi: 10.1007/s40265-015-0536-1.
  • PMID: 26137203
    Phipps C, Chen Y, Gopalakrishnan S, Tan D: Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development. Ther Adv Hematol. 2015 Jun;6(3):120-7. doi: 10.1177/2040620715572295.
  • PMID: 21187443
    de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, Parren PW: Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011 Feb 1;186(3):1840-8. doi: 10.4049/jimmunol.1003032. Epub 2010 Dec 27.
  • PMID: 20608753
    Keizer RJ, Huitema AD, Schellens JH, Beijnen JH: Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010 Aug;49(8):493-507. doi: 10.2165/11531280-000000000-00000.
  • PMID: 21109694
    van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW, Lokhorst HM, Mutis T: Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica. 2011 Feb;96(2):284-90. doi: 10.3324/haematol.2010.030759. Epub 2010 Nov 25.

Contoh Produk & Brand

Produk: 10 • International brands: 0
Produk
  • Darzalex
    Injection, solution, concentrate • 100 mg/5mL • Intravenous • US • Approved
  • Darzalex
    Solution • 100 mg / 5 mL • Intravenous • Canada • Approved
  • Darzalex
    Solution • 400 mg / 20 mL • Intravenous • Canada • Approved
  • Darzalex
    Injection, solution, concentrate • 20 mg/ml • Intravenous • EU • Approved
  • Darzalex
    Injection, solution, concentrate • 20 mg/ml • Intravenous • EU • Approved
  • Darzalex
    Injection, solution, concentrate • 20 mg/ml • Intravenous • EU • Approved
  • Darzalex
    Injection, solution • 1800 mg • Subcutaneous • EU • Approved
  • Darzalex Faspro
    Injection • - • Subcutaneous • US • Approved
Menampilkan 8 dari 10 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul